Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 17:13:1029598.
doi: 10.3389/fphar.2022.1029598. eCollection 2022.

Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix

Rongyu Liu  1   2 , Xinlin He  1   2 , Zhengyu Li  1   2
Affiliations
Review

Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix

Rongyu Liu et al. Front Pharmacol. .

Abstract

Neuroendocrine carcinoma of the cervix (NECC) is a highly aggressive and rare gynecological malignancy with a poor prognosis. Despite aggressive local and systemic treatments, there are high rates of locoregional recurrence and distant metastases. Therefore, more potent treatments are required to manage NECC. In recent years, emerging immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors, have been used in treating various solid tumors and provide a new direction for immune-targeted therapy for NECC. In this review, we summarize the biomarkers useful for the evaluation of the therapy with PD-1/PD-L1 inhibitors in patients with NECC and the clinical applications and prospects of monotherapy with PD-1/PD-L1 inhibitors and combinations with other therapies in patients with NECC. In some individual case reports, therapeutic strategies with PD-1/PD-L1 inhibitors showed good efficacy. Further studies are needed to confirm the possibility of using PD-1/PD-L1 inhibitors as a standard treatment strategy in NECC.

Keywords: PD-1/PD-L1 inhibitors; PD-L1 expression; biomarkers; immunotherapy; neuroendocrine carcinoma of the cervix.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Alejo M., Alemany L., Clavero O., Quiros B., Vighi S., Seoud M., et al. (2018). Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10, 575 invasive cervical cancer cases. Papillomavirus Res 5, 134–142. 10.1016/j.pvr.2018.03.005 - DOI - PMC - PubMed
    1. Alos L., Hakim S., Larque A. B., de la Oliva J., Rodriguez-Carunchio L., Caballero M., et al. (2016). p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas. Virchows Arch 469 (3), 277–284. 10.1007/s00428-016-1982-1 - DOI - PubMed
    1. Arias-Pinilla G. A., Modjtahedi H. (2021). Therapeutic application of monoclonal antibodies in pancreatic cancer: Advances, challenges, and future opportunities. Cancers (Basel) 13, 1781. 10.3390/cancers13081781 - DOI - PMC - PubMed
    1. Burzawa J., Gonzales N., Frumovitz M. (2015). Challenges in the diagnosis and management of cervical neuroendocrine carcinoma. Expert Rev. Anticancer Ther 15, 805–810. 10.1586/14737140.2015.1047767 - DOI - PubMed
    1. Carroll M. R., Ramalingam P., Salvo G., Fujimoto J., Solis Soto L. M., Phoolcharoen N., et al. (2020). Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. Int. J. Gynecol. Cancer 30, 1303–1307. 10.1136/ijgc-2020-001649 - DOI - PMC - PubMed